Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-DEEM dose-finding study of dabigatran etexilate after acute coronary syndrome
2007-004301-99Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dabigatran in acute coronary syndrome (ACS) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of major and clinically relevant minor bleeding events. Started Nov 2007; status: completed.
02
Drugs
dabigatran
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2007-004301-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004301-99.